

## DETAILED ADVANCE PROGRAMME

### GENERAL SESSIONS

#### MONDAY 21 SEPTEMBER 2009

■ 09:00-10:50

##### Opening Session

*Chair: A.M.M. Eggermont (The Netherlands)*

##### Opening addresses

##### ECCO lifetime achievement award

*To be nominated*

##### Drug discovery in the p53 pathway

*Speaker: D. Lane (United Kingdom)*

##### Old drugs vs new drugs and new levels of complexity

*Speaker: J.-P. Armand (France)*

■ 13:30-14:30

##### Special Session: Cancer treatment in emerging countries

*Chair: J. Jassem (Poland)*

##### Facing increasing costs of cancer care: Polish experience

*Speaker: M. Krzakowski (Poland)*

##### Management of breast cancer in limited-resource countries

*Speaker: A. Eniu (Romania)*

##### Discussion and roundup

#### WEDNESDAY 23 SEPTEMBER 2009

■ 09:00-11:00

##### Joint ECCO – ASCO Symposium: Controversies in individualised management of prostate cancer

*Chair: M. Baumann (Germany)*

*Chair: D. Blayney (USA)*

##### Bioinformatics and gene discovery

*Speaker: K. Pienta (USA)*

##### Active surveillance activities in Europe for prostate cancer

*Speaker: C.H. Bangma (The Netherlands)*

##### Watchful waiting in patients with prostate cancer in USA

*Speaker: H. Ballentine Carter (USA)*

##### (Bio) Imaging guided selection and application of personalised radiotherapy

*Speaker: V. Khoo (United Kingdom)*

■ 14:45-16:45

##### Educational Symposium: Advances in neuroendocrine tumours

*Chair: K. Oberg (Sweden)*

##### Surgical aspects of neuroendocrine tumours

*Speaker: G. Åkerström (Sweden)*

##### Lung tumours with neuroendocrine differentiation

*Speaker: W.D. Travis (USA)*

##### Multiple endocrine neoplasia type 2 (MEN2)

*Speaker: K. Frank-Raue (Germany)*

##### Role of radiopharmaceuticals in the diagnosis and treatment of neuroendocrine tumours (NETs)

*Speaker: I.J. Virgolini (Austria)*

### PRESIDENTIAL SESSIONS

#### MONDAY 21 SEPTEMBER 2009

■ 13:15-16:00

##### Presidential Session I: The platform for translational cancer research

*Chair: A.M.M. Eggermont (The Netherlands)*

*Chair: J. Celis (Denmark)*

To be announced

#### TUESDAY 22 SEPTEMBER 2009

■ 12:30-14:30

##### Presidential Session II

##### Hamilton-Fairley Award Lecture

##### ECCO – Pezcoller Award Lecture

##### Late breaking and best abstracts

#### WEDNESDAY 23 SEPTEMBER 2009

■ 12:30-14:30

##### Presidential Session III

##### ECCO Clinical Research Award Lecture

##### Late breaking and best abstracts

#### THURSDAY 24 SEPTEMBER 2009

■ 09:00-11:00

##### Presidential Session IV

##### Late breaking and best abstracts

■ 12:30-14:30

##### Presidential Session V

##### Closing session

### KEYNOTE LECTURES

#### TUESDAY 22 SEPTEMBER 2009

■ 11:15-12:00

##### Keynote Lecture

##### Targeting the cell cycle in cancer

*Speaker: M. Barbacid (Spain)*

#### WEDNESDAY 23 SEPTEMBER 2009

■ 11:15-12:00

##### Keynote Lecture

##### Insights into the cancer cell, stem cell interface through systems biology

*Speaker: F. Buchholz (Germany)*

### SOCIETY SESSIONS

#### MONDAY 21 SEPTEMBER 2009

■ 11:00-13:00

##### Society Session: European Society for Therapeutic Radiology and Oncology (ESTRO)

*Chair: V. Gregoire (Belgium)*

##### Klaas Breur award lecture

*Award Lecturer: P. Lambin (Belgium)*

##### Emmanuel Van der Schueren award lecture

*Award Lecturer: M. Coffey (Ireland)*

*Honorary member: W. Oyen (The Netherlands)*

*Honorary member: P. Harari (USA)*

*Honorary member: A.L. Børresen-Dale (Norway)*

## ■ 11:00-13:00

**Society session: The European Society for Paediatric Oncology (SIOPE)***Chair: K. Pritchard-Jones (United Kingdom)**Chair: R. Ladenstein (Austria)***Award Lecture***Award Lecturer: To be announced*

Proffered papers (6-8 papers)

**TUESDAY 22 SEPTEMBER 2009**

## ■ 09:00-11:00

**Society Session: European Association for Cancer Research (EACR)****EACR Lecture***Session to be announced***Society session: European Society for Medical Oncology (ESMO) Awards Session***Chair: J. Baselga (Spain)***ESMO presentation***Speaker: J. Baselga (Spain)*

ESMO Award presented by J. Baselga

ESMO Lifetime Achievement Award (supported by GlaxoSmithKline) presented by J. Baselga

ESMO Lifetime Achievement Award Lecture

*Award Lecturer: To be announced*

ESMO Exam (20th anniversary) and Award presented by C. Bokemeyer (Germany)

Palliative Care Designated Centre accreditation

*Speaker: R. Catane (Israel)*

Fellowship Programme and Awards

*Speaker: M. Piccart (Belgium)***WEDNESDAY 23 SEPTEMBER 2009**

## ■ 09:00-11:00

**Society Session: European Society of Surgical Oncology (ESSO)****How to manage the patient who presents with stage IV colorectal cancer***Chair: I. Taylor (United Kingdom)*

ESSO Award Lecture : Numbers and the dilemma

*Speaker: T. Wiggers (The Netherlands)***The role of the medical oncologist***Speaker: R. Glynne-Jones (United Kingdom)***The role of the radiation oncologist***Speaker: V. Valentini (Italy)***The role of the liver surgeon***Speaker: R. Adam (France)***The role of the colorectal surgeon***Speaker: T. Wiggers (The Netherlands)*

Panel discussion

## ■ 09:00-11:00

**ESMO Special Session: ESMO clinical recommendations session****Introduction***Chair: N. Paulidis (Greece)**Chair: R.A. Stahel (Switzerland)***Introduction***Speaker: N. Paulidis (Greece)***Renal cell cancer presentation***Speaker: To be announced***Renal cell cancer discussion***Speaker: To be announced***Cancer pain presentation***Speaker: To be announced***Cancer pain discussion***Speaker: To be announced***Head and neck cancer presentation***Speaker: To be announced***Head and neck cancer discussion***Speaker: To be announced***Conclusions***Speaker: R.A. Stahel (Switzerland)*

## ■ 14:45-16:45

**Society session: European Oncology Nursing Society (EONS)****The future is ambulatory care***Chair: S. Kav (Turkey)**Chair: To be announced***Presentation of the EONS Distinguished Merit Award winner***Speaker: S. Faithfull (United Kingdom)***Distinguished Merit Award Lecturer***Award Lecturer: To be nominated***Introduction***Speaker: S. Kav (Turkey)*

A randomised controlled trial of a symptom-orientated home care nursing programme in patients with colorectal and breast cancer receiving oral chemotherapy

*Speaker: A. Molassiotis (United Kingdom)*

Cancer supportive care - creating opportunities within the DRG-system

*Speaker: P. Riemer-Hommel (Germany)*

Ambulatory cancer care for the older person

*Speaker: To be announced*

Concluding remarks

*Speaker: To be announced***THURSDAY 24 SEPTEMBER 2009**

## ■ 09:00-11:00

**ESMO Special Session: Current challenges of biopharmaceuticals and regulatory recommendations****Introduction***Chair: J. Baselga (Spain)**Chair: F. Ciardiello (Italy)*

Targeted therapies in the oncology setting: An overview

*Speaker: To be announced*

Biosimilars: issues facing clinicians

*Speaker: To be announced*

Biosimilars: The industry perspective

*Speaker: To be announced*

Approval strategies with new agents: The need to redefine comparator arms

*Speaker: To be announced*

Approval strategies with new agents: A regulatory perspective

*Speaker: To be announced*

Conclusions

*Speaker: To be announced*

## BASIC SCIENCE

### MONDAY 21 SEPTEMBER 2009

■ 08:00-08:45

**Teaching Lecture: Micro RNA's and their antagonists as novel therapeutics**

*Speaker: To be announced*

■ 11:00-13:00

**Scientific Symposium: The hypoxia pathway in tumour progression and therapy**

*Chair: J. Pouyssegur (France)*

*Chair: V. Jendrossek (Germany)*

**Introduction**

*Speaker: J. Pouyssegur (France)*

**Oxygen sensing, HIF hydroxylases and new cancer targets**

*Speaker: W.G. Kaelin, Jr (USA)*

**Multitasking by pVHL in tumour suppression**

*Speaker: W. Krek (Switzerland)*

**Hypoxia-inducible factor 1 in cancer pathogenesis and therapy**

*Speaker: G. Semenza (USA)*

**Hypoxia signalling, metabolism and cancer**

*Speaker: J. Pouyssegur (France)*

**Concluding remarks**

*Speaker: V. Jendrossek (Germany)*

### TUESDAY 22 SEPTEMBER 2009

■ 13:30-14:30

**Special Session: Synthetic lethality as a novel strategy of cancer therapy**

*Chair: R. Bernards (The Netherlands)*

**Hitting cancer where it hurts most: the RNAi strategy to discover synthetic lethal interactions in cancer**

*Speaker: R. Beijersbergen (The Netherlands)*

**Synthetic lethality - a novel strategy of cancer therapy**

*Speaker: J. Downward (United Kingdom)*

**Discussion and roundup**

■ 14:45-16:45

**Scientific Symposium: The DNA damage response in cancer: role in tumorigenesis and targeted therapy**

*Chair: J. Bartek (Denmark)*

*Chair: T. Helleday (United Kingdom)*

**Introduction**

*Speaker: T. Helleday (United Kingdom)*

**DNA damage responses as a barrier to tumorigenesis**

*Speaker: J. Bartek (Denmark)*

**The DNA damage response: clues to carcinogenesis - and therapy**

*Speaker: Y. Shiloh (Israel)*

**Exploiting cancer defects in targeted therapy**

*Speaker: T. Helleday (United Kingdom)*

**DNA polymerases and cancer**

*Speaker: U. Hübscher (Switzerland)*

**Concluding remarks**

*Speaker: J. Bartek (Denmark)*

### WEDNESDAY 23 SEPTEMBER 2009

■ 08:00-08:45

**Teaching Lecture: Chromatin remodelling and cancer**

*Speaker: Z. Herceg (France)*

■ 14:45-16:45

**Educational Symposium: Oncogenes revisited**

*Chair: W. Gullick (United Kingdom)*

**The epidermal growth factor system of ligands and receptors in cancer**

*Speaker: W. Gullick (United Kingdom)*

**RAS**

*Speaker: To be announced*

**The role of mTOR in cancer**

*Speaker: S. Faivre (France)*

**P53: balancing tumour suppression and implications for the clinic**

*Speaker: V. Rotter (Israel)*

### THURSDAY 24 SEPTEMBER 2009

■ 11:15-12:15

**Special Session: Mouse models of cancer**

*Chair: A. Berns (The Netherlands)*

**Identification of cancer genes and their collaborative networks by large-scale mutagenesis in tumour prone mice**

*Speaker: A. Berns (The Netherlands)*

**Title: To be announced**

*Speaker: To be announced*

**Discussion and roundup**

## BREAST CANCER - EARLY AND ADVANCED DISEASE

### MONDAY 21 SEPTEMBER 2009

■ 08:00-08:45

**Teaching Lecture: Challenges of neoadjuvant chemotherapy in breast cancer**

*Speaker: F. Andre (France)*

■ 16:15-18:15

**Educational Symposium: Clinical relevance of the triple negative breast cancer concept**

*Chair: I. Ellis (United Kingdom)*

**Pathological definition of triple negative breast cancer**

*Speaker: G. Viale (Italy)*

**The genetic basis of the concept**

*Speaker: L.J. van 't Veer (The Netherlands)*

**Prognostic implications**

*Speaker: C. Caldas (United Kingdom)*

**Therapeutic approach of early and advanced triple negative breast cancer**

*Speaker: C. Jackisch (Germany)*

### TUESDAY 22 SEPTEMBER 2009

■ 08:00-08:45

**Teaching Lecture: Bisphosphonates for care and cure**

*Speaker: J.-J. Body (Belgium)*

■ 14:45-16:45

**Scientific Symposium: Targeted therapy in breast cancer**

*Chair: C. Zielinski (Austria)*

*Chair: M. De Laurentis (Italy)*

**Introduction**

*Speaker: M. De Laurentis (Italy)*

**Optimising anti-HER2 therapy in early breast cancer**

*Speaker: M. Piccart (Belgium)*

**Anti-HER2 therapy treatment after progression**

*Speaker: G. von Minckwitz (Germany)*

**Antiangiogenic drugs - quo vadis?**

*Speaker: D. Miles (United Kingdom)*

**Combinations of endocrine agents and new targeted drugs: where do we stand?**

*Speaker: N. Harbeck (Germany)*

**Concluding remarks**

*Speaker: C. Zielinski (Austria)*

■ 17:00-18:00

**Debate: This house believes that it is appropriate to give adjuvant chemotherapy for endocrine responsive tumours**

*Moderator: F. Cardoso (Belgium)*  
*Speaker in favour: J. Crown (Ireland)*  
*Seconder: M. Gnant (Austria)*  
*Speaker against: A. Di Leo (Italy)*  
*Seconder: M. Untch (Germany)*

**WEDNESDAY 23 SEPTEMBER 2009**

■ 08:00-08:45

**Teaching Lecture: Late cardiac and carcinogenic effects of radiotherapy**  
*Speaker: C. Correa (USA)*

■ 09:00-11:00

**Scientific Symposium: Is cytotoxic treatment outdated in advanced or early breast cancer?**

*Chair: M. Colleoni (Italy)*  
*Chair: V. Semiglazov (Russian Federation)*

**Introduction**

*Speaker: M. Colleoni (Italy)*

**New cytotoxics - are there any and are they still needed?**

*Speaker: A. Awada (Belgium)*

**Targeted regimes without cytotoxics - are they ready for prime time?**

*Speaker: F. Andre (France)*

**Role of maintenance chemotherapy in advanced breast cancer**

*Speaker: P. Gascon (Spain)*

**Can we identify patients who do not benefit from adjuvant chemotherapy?**

*Speaker: F. Cardoso (Belgium)*

**Concluding remarks**

*Speaker: V. Semiglazov (Russian Federation)*

**THURSDAY 24 SEPTEMBER 2009**

■ 08:00-08:45

**Teaching Lecture: Special features of lobular cancer implications for management**

*Speaker: B.C. Pestalozzi (Switzerland)*

■ 09:00-11:00

**Scientific Symposium: Optimising therapy of young women with early breast cancer**

*Chair: M. Kaufmann (Germany)*  
*Chair: O. Pagani (Switzerland)*

**Introduction**

*Speaker: M. Kaufmann (Germany)*

**Epidemiology and prognosis of breast cancer in very young population**

*Speaker: P. Tai (Canada)*

**Adjuvant therapy of very young women with early breast cancer**

*Speaker: O. Pagani (Switzerland)*

**Strategies to preserve fertility in young breast cancer patients**

*Speaker: B. Gerber (Germany)*

**Child-bearing in breast cancer survivors**

*Speaker: N. Kroman (Denmark)*

**Concluding remarks**

*Speaker: O. Pagani (Switzerland)*

■ 11:15-12:15

**Special Session: Locoregional control of advanced breast cancer**

*Chair: L. Cataliotti (Italy)*

**The role of the surgeon**

*Speaker: E.J.T. Rutgers (The Netherlands)*

**Locoregional control in metastasized breast cancer, the role of the radiation oncologist**

*Speaker: G. van Tienhoven (The Netherlands)*

**Discussion and roundup**

**CANCER IN THE ELDERLY**

**TUESDAY 22 SEPTEMBER 2009**

■ 08:00-08:45

**Teaching Lecture: Biology of cancer and aging**

*Speaker: D. Van Heemst (The Netherlands)*

■ 13:30-14:30

**Special Session: Breast cancer in the elderly**

*Moderator: E. Brain (France)*

**Elderly patients - a surgical perspective**

*Speaker: W. Jonat (Germany)*

**Elderly patients - a medical perspective**

*Speaker: H. Wildiers (Belgium)*

**Discussion and roundup**

■ 14:45-16:45

**Scientific Symposium: Clinical management of the elderly**

*Chair: R.A. Audisio (United Kingdom)*  
*Chair: M. Aapro (Switzerland)*

**Introduction**

*Speaker: R.A. Audisio (United Kingdom)*

**Geriatric assessment**

*Speaker: C. Terret (France)*

**Radiotherapy**

*Speaker: I. Kunkler (United Kingdom)*

**Surgery**

*Speaker: R.A. Audisio (United Kingdom)*

**Systemic therapy**

*Speaker: M. Extermann (USA)*

**Concluding remarks**

*Speaker: M. Aapro (Switzerland)*

**CENTRAL NERVOUS SYSTEM**

**MONDAY 21 SEPTEMBER 2009**

■ 13:30-14:30

**Special Session: Immunotherapy and vaccination for malignant glioma**

*Chair: P.Y. Dietrich (Switzerland)*

**Introduction**

*Speaker: P.Y. Dietrich (Switzerland)*

**Clinical applications - lessons from paediatrics**

*Speaker: S. van Gool (Belgium)*

**Vaccination for glioma - results and experience**

*Speaker: A.F. Carpentier (France)*

**Discussion and roundup**

**TUESDAY 22 SEPTEMBER 2009**

■ 08:00-08:45

**Teaching Lecture: Re-irradiation in brain tumours - evidence, indications and limitations**

*Speaker: S. Short (United Kingdom)*

■ 13:30-14:30

**Debate: This house believes that molecular markers are helpful for selecting therapies for malignant glioma**

*Moderator: R. Stupp (Switzerland)*  
*Speaker in favour: M. Weller (Germany)*  
*Seconder: G. Reifenberger (Germany)*  
*Speaker against: M. Brada (United Kingdom)*  
*Seconder: M.J. van den Bent (The Netherlands)*

■ 14:45-16:45

**Scientific Symposium: Investigating novel targets and anti-angiogenic agents in brain tumours**

*Chair: K. Lamszus (Germany)*  
*Chair: M.J. van den Bent (The Netherlands)*

**Introduction**

*Speaker: K. Lamszus (Germany)*

**Anti-EGFR and anti-angiogenic therapy - from mice to men**

*Speaker: K. Lamszus (Germany)*

**PTEN inhibition as a target***Speaker: I.K. Mellingshoff (USA)***Novel molecular targets in the clinic***Speaker: U. Bogdahn (Germany)***Combining the adhesion pathway inhibition with radiotherapy - from the bench to the clinic***Speaker: E. Cohen-Jonathan-Moyal (France)***Concluding remarks***Chair: M.J. van den Bent (The Netherlands)***DIAGNOSTIC / BIOMARKERS****TUESDAY 22 SEPTEMBER 2009****13:30-14:30****Debate: This house believes that we should abandon routine embedding of tumour tissues in paraffin***Moderator: R. Bernards (The Netherlands)**Speaker in favour: To be announced**Seconder: L.J. van 't Veer (The Netherlands)**Speaker against: I. Ellis (United Kingdom)**Seconder: Sir N. Wright (United Kingdom)***14:45-16:45****Scientific Symposium: Biomarkers in early clinical drug development***Chair: J. Soria (France)**Chair: E. Calvo (Spain)***Introduction***Speaker: E. Calvo (Spain)***Overview of the biomarker problem***Speaker: D. Sidransky (USA)***The need for robust statistical designs to bring biomarkers to the clinic***Speaker: R. Simon (USA)***Circulating tumour cells in early clinical trials***Speaker: J. de Bono (United Kingdom)***Genomics in early clinical trials***Speaker: L. Pusztai (USA)***Clinical biomarkers and imaging for radiotherapy-induced cell death***Speaker: M. Verheij (The Netherlands)***Concluding remarks***Speaker: J. Soria (France)***DRUG DEVELOPMENT****WEDNESDAY 23 SEPTEMBER 2009****08:00-08:45****Teaching Lecture: Pharmacokinetics in oncology drug development***Speaker: C.H. Takimoto (USA)***17:00-18:00****Debate: This house believes that traditional Phase II trials are a waste of time and money***Moderator: A. Awada (Belgium)**Speaker in favour: R. Kaplan (United Kingdom)**Seconder: M. Buyse (Belgium)**Speaker against: A. Sobrero (Italy)**Seconder: S.M. Bentzen (USA)***THURSDAY 24 SEPTEMBER 2009****09:00-11:00****Educational Symposium: Management and interpretation of novel toxicities of molecular targeted therapies***Chair: C. Twelves (United Kingdom)***Skin toxicities of targeted therapies***Speaker: S. Tejpar (Belgium)***Renal toxicity***Speaker: J. Carles (Spain)***Hypertension and cardiotoxicity of molecularly targeted cancer agents***Speaker: L.L. Siu (Canada)***Gastrointestinal toxicities of novel agents in cancer therapy***Speaker: G. Perlemuter (France)***EPIDEMIOLOGY, PRIMARY AND SECONDARY PREVENTION****WEDNESDAY 23 SEPTEMBER 2009****13:30-14:30****Special Session: Defining optimal strategies for HPV vaccination***Chair: S. Franceschi (France)***Post-vaccine surveillance***Speaker: J. Dillner (Sweden)***Issues in combining cervical screening and vaccination***Speaker: J. Cuzick (United Kingdom)***Discussion and roundup****14:45-16:45****Scientific Symposium: Cancer prevention in Europe***Chair: J.W. Coebergh (The Netherlands)**Chair: P. Boffetta (France)***Introduction***Speaker: J.W. Coebergh (The Netherlands)***The causes of cancer***Speaker: P. Boffetta (France)***Closing the cancer gap in Europe***Speaker: W. Zatonski (Poland)***Priorities in cancer prevention - the Eurocadet project***Speaker: J.W. Coebergh (The Netherlands)***Frontiers of cancer prevention research***Speaker: L. Vatten (Norway)***Concluding remarks***Speaker: P. Boffetta (France)***THURSDAY 24 SEPTEMBER 2009****11:15-12:15****Special Session: Clinical implications of new discoveries in cancer genetics***Chair: T. Bishop (United Kingdom)***Genetic factors in breast cancer***Speaker: D. Easton (United Kingdom)***Genetic factors in lung cancer***Speaker: P.J. Brennan (France)***Discussion and roundup****GASTROINTESTINAL MALIGNANCIES - COLORECTAL CANCER****MONDAY 21 SEPTEMBER 2009****08:00-08:45****Teaching Lecture: Genomic profiling of colorectal cancer***Speaker: P.G. Johnston (Ireland)***15:30-17:30****Educational Symposium: Systemic treatment of advanced colorectal cancer***Chair: A. Sobrero (Italy)***Systematic treatment of advanced colorectal cancer***Speaker: C.-H. Kohne (Germany)***Chemotherapy - which drugs and when?***Speaker: C.J.A. Punt (The Netherlands)***How to integrate biologicals in the continuum of care?***Speaker: J. Cassidy (United Kingdom)***Impact of molecular markers on treatment selection***Speaker: E. Van Cutsem (Belgium)***New approaches and targets***Speaker: J. Tabernero (Spain)***Discussion****TUESDAY 22 SEPTEMBER 2009****08:00-08:45****Teaching Lecture: The KRAS story and beyond***Speaker: P. Laurent Puig (France)*

## ■ 14:45-16:45

**Scientific Symposium: Locally-advanced rectal cancer***Chair: L. Pahlman (Sweden)**Chair: D. Sebag-Montefiorie (United Kingdom)***Introduction***Speaker: L. Pahlman (Sweden)***Rectal cancer staging: which method is optimal?***Speaker: R.G.H. Beets-Tan (The Netherlands)***Chemoradiation as neoadjuvant treatment: which schedule is best?***Speaker: D. Sebag-Montefiorie (United Kingdom)***Late complications of local multimodality treatment***Speaker: C.J.H. van de Velde (The Netherlands)***Quality control of rectal surgery, a must?***Speaker: P. Quirke (United Kingdom)***Downstaging of rectal cancer: is sphincter preservation the goal?***Speaker: L. Pahlman (Sweden)***Concluding remarks***Speaker: D. Sebag-Montefiorie (United Kingdom)*

## ■ 17:00-18:00

**Special Session: Deficient mismatch repair (dMMR) in colorectal cancer***Chair: E. Vilar (USA)***dMMR: always genetic and sometimes hereditary***Speaker: N. Hoogerbrugge (The Netherlands)***Should patients with dMMR be treated with chemotherapy?***Speaker: R. Labianca (Italy)***Discussion and roundup****WEDNESDAY 23 SEPTEMBER 2009**

## ■ 08:00-08:45

**Teaching Lecture: Screening for colorectal cancer, where are we now?***Speaker: N. Arber (Israel)*

## ■ 14:45-16:45

**Scientific Symposium: Liver metastases from colorectal cancer***Chair: B. Nordlinger (France)**Chair: G. Poston (United Kingdom)***Introduction***Speaker: B. Nordlinger (France)***New surgical developments***Speaker: R. Adam (France)***Radiofrequency ablation, a new standard?***Speaker: T.J.M. Ruers (The Netherlands)***Which staging method is optimal?***Speaker: W.J.G. Oyen (The Netherlands)***Systemic treatment***Speaker: H.J. Schmoll (Germany)***Multidisciplinary perspective***Speaker: G. Poston (United Kingdom)***GASTROINTESTINAL MALIGNANCIES - NON-COLORECTAL CANCER****WEDNESDAY 23 SEPTEMBER 2009**

## ■ 17:00-18:00

**Debate: This house believes that upfront chemoradiotherapy is a valid option in locally-advanced pancreatic cancer***Moderator: J. Neoptolemos (United Kingdom)**Speaker in favour: G. van Tienhoven (The Netherlands)**Seconder: V. Budach (Germany)**Speaker against: B. Chauffert (France)**Seconder: I. Chau (United Kingdom)***THURSDAY 24 SEPTEMBER 2009**

## ■ 08:00-08:45

**Teaching Lecture: Current standards and options in the treatment of squamous cell esophageal cancer***Speaker: C. Mariette (France)*

## ■ 09:00-11:00

**Scientific Symposium: New directions in the treatment of gastric cancer***Chair: J. Tabernero (Spain)**Chair: F. Lordick (Germany)***Introduction***Speaker: J. Tabernero (Spain)***Changing epidemiology of gastric cancer - influence on treatment strategies and outcome***Speaker: Y.-K. Kang (South Korea)***Optimal initial work-up and surgical treatment in 2009?***Speaker: C.J.H. van de Velde (The Netherlands)***Perioperative treatment - current standards and next steps***Speaker: P. Rougier (France)***Current chemotherapy options for advanced disease***Speaker: E. Van Cutsem (Belgium)***Integration of targeted therapies***Speaker: J. Tabernero (Spain)***Concluding remarks***Speaker: F. Lordick (Germany)*

## ■ 11:15-12:15

**Special Session: Endoscopic treatment of gastroesophageal cancer***Chair: J.R. Armengol - Miro (Spain)***New endoscopic imaging techniques for the detection of early lesions***Speaker: R. Kiesslich (Germany)***Multi-modality therapy for early Barrett's neoplasia***Speaker: J. Bergman (The Netherlands)***Discussion and roundup****GENITOURINARY MALIGNANCIES - OTHER****MONDAY 21 SEPTEMBER 2009**

## ■ 13:30-14:30

**Special Session: Bladder cancer in the elderly - issues on operation and choice of chemotherapy***Chair: R. De Wit (The Netherlands)***Surgery for bladder cancer in elderly patients: risk, benefit and selection of technique***Speaker: A. Stenzl (Germany)***Unfit patient(s)***Speaker: R. De Wit (The Netherlands)***Radiotherapy view***Speaker: J. Dunst (Germany)***Discussion and roundup****WEDNESDAY 23 SEPTEMBER 2009**

## ■ 08:00-08:45

**Teaching Lecture: Current treatment of high risk testis cancer***Speaker: H.J. Schmoll (Germany)*

## ■ 13:30-14:30

**Special Session: What is new in the pathogenesis of urothelial cancer?***Chair: T.F. Orntoft (Denmark)***Hereditary factors in bladder cancer***Speaker: L.A. Kiemeny (The Netherlands)***Histopathological profile of bladder cancer***Speaker: A. Lopez-Beltran (Spain)***Genomic alterations in urothelial carcinoma subgroups***Speaker: M. Knowles (United Kingdom)***Discussion and roundup**

■ 14:45-16:45

**Scientific Symposium: What are the side-effects of therapy in mRCC and how to handle them?**

Chair: Z. Kirkali (Turkey)  
Chair: B. Escudier (France)

**Introduction**

Speaker: Z. Kirkali (Turkey)

**Tyrosine kinase inhibitors (TKIs)**

Speaker: T. Eisen (United Kingdom)

**mTOR inhibitors, bevacizumab**

Speaker: B. Escudier (France)

**Do combination and sequential therapies have increased side-effects?**

Speaker: C. Porta (Italy)

**Cytokines and vaccines**

Speaker: P. Mulders (The Netherlands)

**Adjusting therapy in the elderly patient**

Speaker: S. Negrier (France)

**Concluding remarks**

Speaker: B. Escudier (France)

■ 17:00-18:00

**Debate: This house believes that sequential use of TKIs does make sense in renal cancer**

Moderator: B. Escudier (France)  
Speaker in favour: T. Eisen (United Kingdom)  
Seconder: J. Bellmunt (Spain)  
Speaker against: A. Ravaud (France)  
Seconder: P. Mulders (The Netherlands)

**GENITOURINARY MALIGNANCIES - PROSTATE CANCER**

**MONDAY 21 SEPTEMBER 2009**

■ 08:00-08:45

**Teaching Lecture: New agents for metastatic prostate cancer**  
Speaker: K. Fizazi (France)

■ 15:30-17:30

**Scientific Symposium: Prostate cancer**

Chair: I.F. Tannock (Canada)  
Chair: K. Fizazi (France)

**Introduction**

Speaker: I.F. Tannock (Canada)

**Changing definition of hormone refractory**  
Speaker: K. Fizazi (France)

**Advances in molecular understanding of prostate cancer**  
Speaker: J. Schalken (The Netherlands)

**Prostate cancer: the bone paradigm...**

Speaker: B. Tombal (Belgium)

**Drug resistance in metastatic PCA**

Speaker: I.F. Tannock (Canada)

**Concluding remarks**

Speaker: K. Fizazi (France)

**TUESDAY 22 SEPTEMBER 2009**

■ 13:30-14:30

**Special Session: Side-effects of treatment for early disease - which is the best?**

Chair: M. Wirth (Germany)

**Surgery**

Speaker: M. Wirth (Germany)

**Radiotherapy**

Speaker: C. Parker (United Kingdom)

**Active surveillance**

Speaker: C.H. Bangma (The Netherlands)

**Discussion and roundup**

■ 14:45-16:45

**Educational Symposium: Prostate cancer - therapeutic options after relapse**

Chair: T. de Reijke (The Netherlands)  
Chair: T. Wiegel (Germany)

**Treatment of local progression after radiotherapy**

Speaker: T. de Reijke (The Netherlands)

**Salvage radiotherapy in patients with persisting/rising PSA after radical prostatectomy for prostate cancer**

Speaker: T. Wiegel (Germany)

**Hormonal treatment for progression**

Speaker: K. Miller (Germany)

**Chemotherapy in men with hormone-refractory prostate cancer**

Speaker: R. De Wit (The Netherlands)

■ 17:00-18:00

**Debate: This house believes that radical surgery is better than radical radiation therapy for locally-advanced prostate cancer**

Moderator: J. Bellmunt (Spain)  
Speaker in favour: H. van Poppel (Belgium)  
Seconder: R. Miralbell (Switzerland)  
Speaker against: C. Parker (United Kingdom)  
Seconder: M. Graefen (Germany)

**GYNAECOLOGICAL CANCER**

**WEDNESDAY 23 SEPTEMBER 2009**

■ 08:00-08:45

**Teaching Lecture: Endometriosis and cancer**  
Speaker: To be announced

■ 13:30-14:30

**Special Session: Immune system and ovarian cancers**

Chair: G. Coukos (USA)

**Harnessing the immune system for ovarian cancer therapy**

Speaker: G. Coukos (USA)

**Clinical trials on immunotherapy in ovarian cancer**

Speaker: H. Nijman (The Netherlands)

**Discussion and roundup**

**THURSDAY 24 SEPTEMBER 2009**

■ 08:00-08:45

**Teaching Lecture: Overview of cervical vaccination**

Speaker: E. Joura (Austria)

■ 09:00-11:00

**Scientific Symposium: New targets for ovarian cancer**

Chair: N. Colombo (Italy)  
Chair: C. Sessa (Switzerland)

**Introduction**

Speaker: N. Colombo (Italy)

**Biology of tumour angiogenesis and potential biomarkers of effects**

Speaker: C. Ruegg (Switzerland)

**Clinical experience with antiangiogenic targeting in ovarian cancer**

Speaker: M. Bookman (USA)

**Emerging new targets**

Speaker: S.B. Kaye (United Kingdom)

**Molecular determinants of acquired resistance**

Speaker: S. De Jong (The Netherlands)

**Concluding remarks**

Speaker: C. Sessa (Switzerland)

**HAEMATOLOGICAL MALIGNANCIES AND MYELOMA**

**MONDAY 21 SEPTEMBER 2009**

■ 08:00-08:45

**Teaching Lecture: Therapy of diffuse large cell lymphon (DLCL)**

Speaker: M. Pfreundschuh (Germany)

■ 13:30-14:30

**Special Session: Secondary leukaemia following chemo or radiotherapy**

Chair: D. Grimwade (United Kingdom)

**Molecular pathogenesis and biology of secondary leukaemias**

*Speaker: D. Grimwade (United Kingdom)*

**Secondary leukaemia after breast cancer**

*Speaker: F. Lo-Coco (Italy)*

**Secondary leukaemia after Hodgkin's disease**

*Speaker: A. Engert (Germany)*

**Discussion and roundup**

■ 15:30-17:30

**Scientific Symposium: New drugs and novel therapeutic targets for haematological malignancies**

*Chair: J.F. San Miguel (Spain)*

*Chair: M. Hallek (Germany)*

**Introduction**

*Speaker: M. Hallek (Germany)*

**New drugs and novel therapeutic principles in multiple myeloma**

*Speaker: J.F. San Miguel (Spain)*

**Tyrosine kinase inhibitors in myeloid malignancies**

*Speaker: A. Burnett (United Kingdom)*

**JAK-2 and its inhibitors for myeloid neoplasias**

*Speaker: A. Tefferi (USA)*

**HDACs inhibitors for lymphoid neoplasias**

*Speaker: M. Kirschbaum (USA)*

**Novel drugs in CLL**

*Speaker: M. Hallek (Germany)*

**Concluding remarks**

*Speaker: J.F. San Miguel (Spain)*

**TUESDAY 22 SEPTEMBER 2009**

■ 08:00-08:45

**Teaching Lecture: Allogeneic transplantation**

*Speaker: G. Ehninger (Germany)*

■ 09:00-11:00

**Scientific Symposium: Role of PET imaging**

*Chair: M. Pfreundschuh (Germany)*

*Chair: M.H. Dreyling (Germany)*

**Introduction**

*Speaker: M. Pfreundschuh (Germany)*

**Haematological oncology: new PET tracers for imaging pathophysiology and response**

*Speaker: S. Reske (Germany)*

**PET imaging of non-Hodgkin lymphoma: defining methodologies for early prediction of response**

*Speaker: C. Haioun (France)*

**Role of FDG-PET and PET/CT in treatment planning of other haematological tumours**

*Speaker: L. Specht (Denmark)*

**Role of PET in clinical trials of novel therapies in haematology**

*Speaker: B. Cheson (USA)*

**Concluding remarks**

*Speaker: M.H. Dreyling (Germany)*

■ 17:00-18:00

**Debate: This house believes that watching and waiting is still an option in indolent lymphomas**

*Moderator: A. Lister (United Kingdom)*

*Speaker in favour: M.H. Dreyling (Germany)*

*Seconder: P. Solal-Celigny (France)*

*Speaker against: M. Ghelmini (Switzerland)*

*Seconder: E. Kimby (Sweden)*

**HEAD AND NECK CANCER**

**MONDAY 21 SEPTEMBER 2009**

■ 08:00-08:45

**Teaching Lecture: Clinical relevance of HPV in head and neck cancer**

*Speaker: M.L. Gillison (USA)*

■ 13:30-14:30

**Special Session: Metastatic neck nodal carcinoma of unknown primary**

*Chair: M. Merlano (Italy)*

**Diagnostic issues and treatment**

*Speaker: M. Merlano (Italy)*

**Radiation therapy**

*Speaker: V. Gregoire (Belgium)*

**Discussion and roundup**

■ 15:30-17:30

**Scientific Symposium: Head and neck cancer treatment - how aggressive should we be?**

*Chair: J. Bernier (Switzerland)*

*Chair: J.B. Vermorken (Belgium)*

**Introduction**

*Speaker: J. Bernier (Switzerland)*

**Local regionally advanced disease - non-surgical approaches**

*Speaker: J. Bourhis (France)*

**Local regionally advanced disease - surgical approaches including postoperative treatment**

*Speaker: R. Knecht (Germany)*

**New developments in larynx preservation**

*Speaker: J.L. Lefebvre (France)*

**Molecular markers predicting outcome**

*Speaker: C. Boshoff (United Kingdom)*

**Prognostic and predictive value of head and neck cancer**

*Speaker: M.L. Gillison (USA)*

**Concluding remarks**

*Chair: J.B. Vermorken (Belgium)*

**TUESDAY 22 SEPTEMBER 2009**

■ 17:00-18:00

**Debate: This house believes that bioradiation can replace chemoradiation in head and neck cancer**

*Moderator: L. Licitra (Italy)*

*Speaker in favour: K.K. Ang (USA)*

*Seconder: J. Overgaard (Denmark)*

*Speaker against: M.R. Posner (USA)*

*Seconder: J.B. Vermorken (Belgium)*

**IMAGING**

**WEDNESDAY 23 SEPTEMBER 2009**

■ 09:00-11:00

**Scientific Symposium: Molecular imaging of cancer**

*Chair: E. Aboagye (United Kingdom)*

*Chair: R. Blasberg (USA)*

**Introduction**

*Speaker: E. Aboagye (United Kingdom)*

**Reporter gene imaging in cancer**

*Speaker: R. Blasberg (USA)*

**Imaging of the tumour microenvironment**

*Speaker: R.J. Gillies (USA)*

**Life and death of the cancer cell-PET imaging of proliferation and apoptosis**

*Speaker: E. Aboagye (United Kingdom)*

**MR imaging of angiogenesis**

*Speaker: G. Jayson (United Kingdom)*

**Concluding remarks**

*Speaker: R. Blasberg (USA)*

**THURSDAY 24 SEPTEMBER 2009**

■ 08:00-08:45

**Teaching Lecture: How to use functional imaging information for radiotherapy planning**

*Chair: V. Khoo (United Kingdom)*

**PET/CT**

*Speaker: V. Gregoire (Belgium)*

**MRI**

*Speaker: A.L. Grosu (Germany)*

■ 11:15-12:15

**Special Session: Established and emerging imaging applications**

*Chair: A.F. Scarsbrook (United Kingdom)*

**MRI: development in 3T and higher field instruments**

*Speaker: A. Heerschap (The Netherlands)*

**PET-CT: has sensitivity and specificity improved for staging and response monitoring?**

*Speaker: G. von Schulthess (Switzerland)*

Discussion and roundup

## LUNG CANCER

### MONDAY 21 SEPTEMBER 2009

■ 08:00-08:45

**Teaching Lecture: Lung cancer screening**

**Radiological screening**

*Speaker: R.J. Van Klaveren (The Netherlands)*

**Biomarkers aspects**

*Speaker: L.M. Montuenga (Spain)*

■ 15:30-17:30

**Scientific Symposium: Genetic aberrations in lung cancer**

*Chair: R. Stahel (Switzerland)*

*Chair: G. Giaccone (USA)*

**Introduction**

*Speaker: R. Stahel (Switzerland)*

**The role of biomarkers in selecting the right targeted agent to combine with chemotherapy**

*Speaker: G. Giaccone (USA)*

**Molecular mechanisms of lung cancer development - how to use our knowledge of molecular biology in more effective therapies**

*Speaker: Y. Yarden (Israel)*

**Genetic aberrations as determinants of response to chemotherapy**

*Speaker: R. Rosell (Spain)*

**EGF receptors**

*Speaker: F. Ciardiello (Italy)*

**Closing remarks**

*Speaker: G. Giaccone (USA)*

### TUESDAY 22 SEPTEMBER 2009

■ 08:00-08:45

**Teaching Lecture: Chest tumours / non-small cell lung cancer / rare tumours**

*Speaker: E. Felip Font (Spain)*

■ 14:45-16:45

**Educational Symposium: Can there be generalised recommendations for multimodality treatment in stage III NSCLC?**

*Chair: J. Vansteenkiste (Belgium)*

**The multidisciplinary of stage III NSCLC**

*Speaker: J. Vansteenkiste (Belgium)*

**Surgical treatment of stage III non-small cell lung cancer (NSCLC)**

*Speaker: P. Van Schil (Belgium)*

**Radiotherapy for stage III non-small cell lung cancer**

*Speaker: F. Mornex (France)*

**Chemotherapy**

*Speaker: W. Eberhardt (Germany)*

**Conclusion**

*Speaker: J. Vansteenkiste (Belgium)*

■ 17:00-18:00

**Special Session: Specific issues in lung cancer management**

*Chair: C. Gridelli (Italy)*

**How to approach oligometastatic disease - is there a role for surgery?**

*Speaker: W. Weder (Switzerland)*

**Stereotactic high dose radiotherapy treatment of early stage NSCLC**

*Speaker: M. Flentje (Germany)*

**Which is the best treatment for non-small lung cancer patients with PS 2?**

*Speaker: C. Gridelli (Italy)*

Discussion and roundup

### WEDNESDAY 23 SEPTEMBER 2009

■ 08:00-08:45

**Teaching Lecture: Treatment of limited disease - small cell lung cancer**

*Speaker: D. De Ruyscher (The Netherlands)*

■ 14:45-16:45

**Scientific Symposium: The management of malignant pleural mesothelioma**

*Chair: D. Waller (United Kingdom)*

*Chair: P. Baas (The Netherlands)*

**Introduction**

*Speaker: D. Waller (United Kingdom)*

**Biology of mesothelioma**

*Speaker: P.A. Zucali (Italy)*

**Chemotherapy**

*Speaker: L. Paz-Ares (Spain)*

**Radiotherapy**

*Speaker: C. Faivre-Finn (United Kingdom)*

**The role of surgery**

*Speaker: D. Waller (United Kingdom)*

**Multidisciplinary perspective**

*Speaker: P. Baas (The Netherlands)*

■ 17:00-18:00

**Debate: This house believes that targeted treatment should be used in all cases with lung cancer**

*Moderator: R. Stahel (Switzerland)*

*Speaker in favour: G. Giaccone (USA)*

*Seconder: J. Soria (France)*

*Speaker against: M. Reck (Germany)*

*Seconder: C. Gridelli (Italy)*

## MELANOMA AND SKIN CANCER

### WEDNESDAY 23 SEPTEMBER 2009

■ 08:00-08:45

**Teaching Lecture: How to perform translational research in melanoma**

*Speaker: A. Spatz (Canada)*

■ 09:00-11:00

**Scientific Symposium: Current avenues in clinical trials for melanoma treatment**

*Chair: P. Lorigan (United Kingdom)*

*Chair: U. Keilholz (Germany)*

**Introduction**

*Speaker: P. Lorigan (United Kingdom)*

**Targeting immune checkpoints: CTLA-4 and related molecules**

*Speaker: U. Keilholz (Germany)*

**Melanoma vaccines - quo vadis?**

*Speaker: G. Parmiani (Italy)*

**Targeting VEGF: sorafenib, axitinib, bevacizumab and others**

*Speaker: P. Lorigan (United Kingdom)*

**Novel agents in clinical development (including bcl-2 antisense)**

*Speaker: K. Flaherty (USA)*

**Concluding remarks**

*Speaker: U. Keilholz (Germany)*

■ 13:30-14:30

**Debate: This house believes that adjuvant treatment should be the standard in stage II-III melanoma**

*Moderator: P. Patel (United Kingdom)*

*Speaker in favour: J. Kirkwood (USA)*

*Seconder: A. Hauschild (Germany)*

*Speaker against: To be announced*

*Seconder: K.M. McMasters (USA)*

## ONCOLOGY NURSING

## MONDAY 21 SEPTEMBER 2009

## ■ 08:00-08:45

**Teaching Lecture: Are we assessing what is important for patients and families?***Speaker: A. Richardson (United Kingdom)*

## ■ 11:00-13:00

**Scientific Symposium: Symptom clusters in cancer therapy***Chair: S. Kav (Turkey)**Chair: To be announced***Introduction***Speaker: S. Kav (Turkey)***What's new, what's best in symptom management?***Speaker: C. Miaskowski (USA)***Evolving paradigms in the management of radiation side-effects***Speaker: L. Sharp (Sweden)***The balance of endocrine therapy, symptom burden and outcomes for cancer survivors***Speaker: L. Fallowfield (United Kingdom)***Complex symptoms in advanced cancer: understanding multidisciplinary approaches***Speaker: E. Ream (United Kingdom)***Concluding remarks***Speaker: To be announced*

## ■ 13:30-14:30

**Special Session: Case-based: linking symptom science to practice***Chair: U. Östlund (Sweden)***Symptom management: a case study***Speaker: C. Miaskowski (USA)***Symptom clusters: a case study***Speaker: E. Ream (United Kingdom)***Discussion and roundup**

## ■ 13:30-14:30

**Special Session: Assessment and measurement in cancer care***Chair: D. Kelly (United Kingdom)***Developing cancer rehabilitation using appropriate assessment of need***Speaker: N. Doyle (United Kingdom)***Using evidence to assess complex symptoms: an education approach in practice***Speaker: M. Krishnasamy (Australia)***Discussion and roundup**

## ■ 15:30-17:30

**Scientific Symposium: After cancer therapy, prevention and promotion***Chair: S. Faithfull (United Kingdom)**Chair: F. Charnay-Sonnek (France)***Introduction***Speaker: S. Faithfull (United Kingdom)***Exercise for disease prevention and health promotion in cancer survivors***Speaker: K.S. Courneya (Canada)***Managing late effects following haematological malignancy and BMT***Speaker: L. Bishop (United Kingdom)***Assessment of young adult survivors needs: building an evidence-based late effects service***Speaker: G. Levitt (United Kingdom)***Optimal approaches to post treatment recovery: multidisciplinary team working***Speaker: To be announced***Concluding remarks***Speaker: F. Charnay-Sonnek (France)*

## TUESDAY 22 SEPTEMBER 2009

## ■ 08:00-08:45

**Teaching Lecture: Cancer and nutrition key determinants of quality of life***Speaker: P. Ravasco (Portugal)*

## ■ 09:00-11:00

**Scientific Symposium: Researching complex clinical issues in cancer care***Chair: S. Kav (Turkey)**Chair: Y. Wengström (Sweden)***Introduction***Speaker: S. Kav (Turkey)***Nursing-sensitive outcomes: what are they and should we be measuring them?***Speaker: D. Doran (Canada)***Selecting appropriate outcome measures for exercise interventions in cancer survivors***Speaker: K.S. Courneya (Canada)***Design and methodological challenges in cancer-related quality of life research***Speaker: T. Kroll (United Kingdom)***Patient-reported outcomes in cancer research***Speaker: G. Velikova (United Kingdom)***Concluding remarks***Speaker: Y. Wengström (Sweden)*

## ■ 13:30-14:30

**Special Session: Palliative cancer care***Chair: S. Faithfull (United Kingdom)***Optimal approaches to persistent and chronic pain: new perspectives on an old problem***Speaker: R. De wit (The Netherlands)***Advanced disease: managing the complex journey of cancer recurrence***Speaker: P. Larkin (Ireland)***Discussion and roundup**

## ■ 14:45-16:45

**Scientific Symposium: Managing emotional concerns***Chair: L. Fallowfield (United Kingdom)**Chair: J. Foubert (Belgium)***Introduction***Speaker: L. Fallowfield (United Kingdom)***Management of depression for people with cancer***Speaker: To be announced***Clinical communication skills and coping, the keys to helping patients***Speaker: J. Foubert (Belgium)***Therapeutic decision-making in adolescents with cancer***Speaker: To be announced***Communicating about illness: family nursing in oncology care***Speaker: U. Östlund (Sweden)***Concluding remarks***Speaker: J. Foubert (Belgium)*

## ■ 17:00-18:00

**Special Session: Case-based: critical moments in cancer therapy***Chair: Sara Faithfull (United Kingdom)***Targeted therapies and reactions to EGFR inhibitors***Speaker: A. Margulies (Switzerland)***Controversies in anaemia: risk of respite***Speaker: L. Bishop (United Kingdom)***Discussion and roundup**

## WEDNESDAY 23 SEPTEMBER 2009

## ■ 08:00-08:45

**Teaching Lecture: Evaluation of quality indicators for cancer services***Speaker: U. Wagner (Switzerland)*

■ 09:00-11:00

**Scientific Symposium: Divergence within cancer nursing roles**

*Chair: S. Faithfull (United Kingdom)*

*Chair: To be announced*

**Introduction**

*Speaker: S. Faithfull (United Kingdom)*

**Revision of professional roles: is this safe and effective?**

*Speaker: M. Laurent (The Netherlands)*

**Evidence of value-added benefit of specialist nursing roles?**

*Speaker: D. Doran (Canada)*

**Developing the potential of community cancer nursing?**

*Speaker: C. Kennedy (United Kingdom)*

**Advancing cancer nursing practice developing competencies for clinical practice**

*Speaker: To be announced*

**Concluding remarks**

*Speaker: To be announced*

■ 13:30-14:30

**Special Session: Using evidence-based cancer nursing practice**

*Chair: Y. Wengström (Sweden)*

**Developing and sustaining evidence-based practice**

*Speaker: To be announced*

**Overcoming the barriers to making change in cancer services**

*Speaker: M. Krishnasamy (Australia)*

**Discussion and roundup**

■ 17:00-18:00

**Special Session: Case-based: leadership and management**

*Chair: J. Foubert (Belgium)*

**Measuring quality at a local level**

*Speaker: To be announced*

**Encouraging innovation in clinical practice**

*Speaker: M. Krishnasamy (Australia)*

**Discussion and roundup**

**THURSDAY 24 SEPTEMBER 2009**

■ 08:00-08:45

**Teaching Lecture: Psycho-science: where do we go from here?**

*Speaker: L.G. Walker (United Kingdom)*

■ 09:00-11:00

**Scientific Symposium: Fertility and sexuality: the development of oncosexology**

*Chair: S. Faithfull (United Kingdom)*

*Chair: L. Incrocci (The Netherlands)*

**Introduction**

*Speaker: S. Faithfull (United Kingdom)*

**Fertility understanding the options after cancer treatment**

*Speaker: L.R. Schouer (USA)*

**Talking about sex: identifying psycho-sexual concerns in the clinic**

*Speaker: I.D. White (United Kingdom)*

**Therapeutic approaches for sexual dysfunction in men treated for prostate cancer**

*Speaker: L. Incrocci (The Netherlands)*

**Education and training staff: how to develop and integrate oncosexology?**

*Speaker: W.L. Gianotten (The Netherlands)*

**Concluding remarks**

*Speaker: L. Incrocci (The Netherlands)*

■ 11:15-12:15

**Special Session: Future trends and EONS projects**

*Chair: To be announced*

*Chair: S. Kav (Turkey)*

**Prostate cancer and supportive care: European training needs analysis**

*Speaker: D. Kelly (United Kingdom)*

**What does the future cancer workforce need to look like?**

*Speaker: S. Faithfull (United Kingdom)*

**Discussion and roundup**

**ONCOPOLICY**

**MONDAY 21 SEPTEMBER 2009**

■ 13:15-16:00

**Presidential Session I: The platform for translational cancer research**

*Chair: A.M.M. Eggermont (The Netherlands)*

*Chair: J. Celis (Denmark)*

*To be announced*

**TUESDAY 22 SEPTEMBER 2009**

■ 09:00-10:00

**Special Session: National cancer plans**

*To be announced*

■ 17:00-18:30

**Forum: Optimising drug development: issues for academia, industry and regulatory bodies**

*Moderator: A.M.M. Eggermont*

*(The Netherlands)*

**Academia panel**

*To be announced*

**Industry panel**

*To be announced*

**Regulatory body panel**

*To be announced*

**WEDNESDAY 23 SEPTEMBER 2009**

■ 09:00-11:00

**Scientific Symposium: High level pharmaceutical forum recommendations**

*To be announced*

**THURSDAY 24 SEPTEMBER 2009**

■ 09:00-11:00

**Educational Symposium: Chemoprevention of major cancers: the latest news**

*Chair: H. Senn (Switzerland)*

**The rational and potential of chemoprevention with special emphasis on breast cancer**

*Speaker: A. Decensi (Italy)*

**Prostate cancer - chemoprevention**

*Speaker: F.H. Schröder (The Netherlands)*

**Colon cancer chemoprevention: ready for practice?**

*Speaker: N. Arber (Israel)*

■ 11:15-12:15

**Special Session: Drug and lifestyle mediated prevention initiatives in Europe**

*Chair: J. Cuzick (United Kingdom)*

**Obesity and overall cancer risk**

*Speaker: A.G. Renehan (United Kingdom)*

**Drug/lifestyle and breast cancer prevention**

*Speaker: J. Cuzick (United Kingdom)*

**Drug/lifestyle and colon cancer prevention**

*Speaker: F. Otto (Switzerland)*

**Discussion and roundup**

## PAEDIATRIC ONCOLOGY

## MONDAY 21 SEPTEMBER 2009

## ■ 08:00-08:45

**Teaching Lecture: New approaches to clinical trial design for rare tumours including childhood cancer**

*Speaker: M. Le Deley (France)*

## ■ 13:30-14:30

**Special Session: Advances in fertility preservation for children and adolescents with cancer**

*Chair: H. Wallace (United Kingdom)*

**Improving success rates of sperm banking in adolescents**

*Speaker: To be announced*

**Advances in ovarian cryopreservation**

*Speaker: J. Donnez (Belgium)*

**Advances in male fertility preservation**

*Speaker: A. Pacey (United Kingdom)*

**Discussion and roundup**

## ■ 15:30-17:30

**Scientific Symposium: How to select a new drug in paediatric oncology**

*Chair: R. Riccardi (Italy)*

*Chair: G. Vassal (France)*

**Introduction**

*Speaker: R. Riccardi (Italy)*

**How to select a new drug in paediatric oncology (including early phase trials in solid tumours)**

*Speaker: G. Vassal (France)*

**Phase I and II trial methodology**

*Speaker: B.J. Morland (United Kingdom)*

**Response assessment in new drug trials**

*Speaker: A.C. Peet (United Kingdom)*

**Phase I/II studies in leukaemia**

*Speaker: A. Biondi (Italy)*

**Ethical aspects of early phase clinical trials in children**

*Speaker: F. Doz (France)*

**Concluding remarks**

*Speaker: G. Vassal (France)*

## TUESDAY 22 SEPTEMBER 2009

## ■ 08:00-08:45

**Teaching Lecture: Advances in fertility preservation for children with cancer**

*Speaker: J. Donnez (Belgium)*

## ■ 09:00-11:00

**Scientific Symposium: Recent breakthroughs and future directions**

*Chair: A. Biondi (Italy)*

*Chair: J.R. Kowalczyk (Poland)*

**Introduction**

*Speaker: A. Biondi (Italy)*

**SIOP brain tumour trials**

*Speaker: F. Doz (France)*

**SIOP Wilms tumour trials**

*Speaker: K. Pritchard-Jones (United Kingdom)*

**SIOP neuroblastoma trials**

*Speaker: R. Ladenstein (Austria)*

**Germ cell tumour trials**

*Speaker: G.C. Calaminus (Germany)*

**SIOPEL liver trials**

*Speaker: P. Czauderna (Poland)*

**I-BFM SG trials on childhood ALL**

*Speaker: A. von Stackelberg (Germany)*

**Concluding remarks**

*Speaker: J.R. Kowalczyk (Poland)*

## ■ 14:45-16:45

**Scientific Symposium: Refining treatment and the cost of the cure - lessons from soft tissue sarcoma in young people**

*Chair: M.C.G. Stevens (United Kingdom)*

*Chair: T.E. Klingebiel (Germany)*

**Introduction**

*Speaker: M.C.G. Stevens (United Kingdom)*

**Stratifying treatment for rhabdomyosarcoma**

*Speaker: O. Oberlin (France)*

**Estimating the total burden of therapy**

*Speaker: M.C.G. Stevens (United Kingdom)*

**Synovial sarcoma: adult vs. paediatric approaches and the need for consensus**

*Speaker: A. Ferrari (Italy)*

**New approaches to the use of radiation therapy in young people: efficacy vs. late effects**

*Speaker: M. Gaze (United Kingdom)*

**Concluding remarks**

*Speaker: T.E. Klingebiel (Germany)*

## WEDNESDAY 23 SEPTEMBER 2009

## ■ 09:00-11:00

**Scientific Symposium: New imaging approaches to response assessment in childhood cancer**

*Chair: A.C. Peet (United Kingdom)*

*Chair: C. Mauz Korholz (Germany)*

**Introduction**

*Speaker: C. Mauz Korholz (Germany)*

**Are current tumour response criteria relevant to the 21st century?**

*Speaker: To be announced*

**Assessing changes in tumour metabolism using magnetic resonance spectroscopy**

*Speaker: A.C. Peet (United Kingdom)*

**Diffusion weighted imaging in the evaluation of response in abdominal tumours**

*Speaker: O. Olsen (United Kingdom)*

**Assessing apoptosis in vivo using targeted contrast agents**

*Speaker: K. Brindle (United Kingdom)*

**Pitfalls in the interpretation of response in Hodgkin's lymphoma: the role of PET imaging**

*Speaker: C. Mauz Korholz (Germany)*

**Concluding remarks**

*Speaker: A.C. Peet (United Kingdom)*

## ■ 13:30-14:30

**Debate: This house believes that teenage and young adult units improve outcomes**

*Moderator: K. Pritchard-Jones (United Kingdom)*

*Speaker in favour: L. Brugieres (France)*

*Second: A.W. Bleyer (USA)*

*Speaker against: D. Korholz (Germany)*

*Second: To be announced*

*Second: To be announced*

## ■ 14:45-16:45

**Scientific Symposium: Advances in leukaemia**

*Chair: A. Biondi (Italy)*

*Chair: M. Schrappe (Germany)*

**Introduction**

*Speaker: A. Biondi (Italy)*

**Leukaemic stem cells and their implications for therapy in childhood leukaemia**

*Speaker: E. Jacobsen (United Kingdom)*

**Genome wide approaches to identify new genetic alteration in childhood leukaemia**

*Speaker: J.R. Downing (USA)*

**Tailored treatment of childhood ALL**

*Speaker: M. Schrappe (Germany)*

**Perspectives in cell and gene therapy of childhood leukaemia**

*Speaker: A. Biondi (Italy)*

**Changing indications for stem cell transplant in leukaemia in children and young adults**

*Speaker: C. Peters (Austria)*

**Concluding remarks**

*Speaker: M. Schrappe (Germany)*

## PATIENT ADVOCACY / ETHICS

### MONDAY 21 SEPTEMBER 2009

■ 11:00-13:00

#### Advocacy Session: Advocacy in practice

Chair: J. Fox (United Kingdom)

#### Opening Lecture: Patient groups - meeting the challenge of sustainable funding

Speaker: S. Kyriakides (Cyprus)

#### An overview of patient advocacy

Speaker: J. Fox (United Kingdom)

Speaker: K. Oliver (United Kingdom)

Speaker: H. Preuss (Germany)

Speaker: H. Tavio (Finland)

Speaker: E. Adarska (Bulgaria)

■ 13:45-15:15

#### Advocacy Session: Informed cancer patients receive better treatment and care

Chair: A. Waldmann (Germany)

#### Surviving childhood cancers

Speaker: A. Brownsdon (United Kingdom)

#### Talking with patients about expensive (unavailable) new cancer drugs

Speaker: L. Fallowfield (United Kingdom)

#### Getting your share of good care - an Eastern European perspective

Speaker: V. Cursaru (Romania)

#### Silent no more: cancer patients as advocates

Speaker: D. Schmitt (Germany)

■ 15:30-17:00

#### Advocacy Session: Access to clinical trials

Chair: J. Geissler (Germany)

#### The patient perspective

Speaker: R. Wilson (United Kingdom)

#### Trial publication and disclosure

Speaker: R. Horton (United Kingdom)

#### Clinical trials registries and databases

Speaker: D. Gherzi (Switzerland)

#### Access to trials: the investigator's perspective

Speaker: A. Hochhaus (Germany)

■ 17:00-18:00

#### Debate: Do patient advocacy groups represent the patients?

Chair: G. Feick (Germany)

Speaker in favour: E. Verschuur-van der Voort (The Netherlands)

Speaker against: T. Hudson (Italy)

### TUESDAY 22 SEPTEMBER 2009

■ 09:00-10:30

#### Advocacy Session: The burden of cancer

Chair: I. Kössler (Sweden)

#### Overview of the burden of cancer in Europe

Speaker: J.W. Coebergh (The Netherlands)

#### Economic burden of cancer on patients

Speaker: A. Leppanen (Sweden)

#### Psychological impact of cancer on the patient

Speaker: J. Corner (United Kingdom)

#### Return to working life with/after cancer

Speaker: S. Rozman (Slovenia)

■ 11:00-12:00

#### Advocacy Session: From patient to partner: evolution of the patient's role in health care

Chair: L. Faulds Wood (United Kingdom)

#### From patient to partner: evolution of the patient's role in health care

Speaker: L. Denis (Belgium)

Speaker: L. Faulds Wood (United Kingdom)

Speaker: J. Foubert (Belgium)

#### Why we need a patient voice in Europe

Speaker: A. Peterle (Slovenia)

■ 13:00-14:30

#### Advocacy Session: Cancer in the workplace

Chair: I. Banks (United Kingdom)

#### Health literacy and active prevention - WHO campaign

Speaker: K. Rokho (Germany)

#### EU plan for a safer workplace

Speaker: F. Alvarez Hidalgo (Belgium)

#### Early symptom recognition, disease management and work balance diagnosis and screening

Speaker: S. Boorman (United Kingdom)

#### Better use of services for migrant workers and cross border treatment

Speaker: M. Carballo (Switzerland)

■ 14:45-16:15

#### Advocacy Session: Improving cancer outcomes through healthy lifestyle choices

Chair: K. Redmond (Switzerland)

#### Benefits of exercise for cancer patients

Speaker: F. Dimeo (Germany)

#### CAM and cancer: the good, the bad and the ugly

Speaker: E. Ernst (United Kingdom)

#### Improving cancer outcomes by promoting medicines adherence

Speaker: K. Redmond (Switzerland)

#### Benefits of a healthy diet for cancer patients

Speaker: F. Berrino (Italy)

■ 16:30-17:30

#### Debate: This house believes that individualised treatment will be the future

Moderator: H. Ludwig (Austria)

Speaker in favour: C. Klein (Germany)

Speaker against: R. Greil (Austria)

## REGULATORY / TRIAL METHODOLOGY / PHARMACY

### MONDAY 21 SEPTEMBER 2009

■ 11:00-13:00

#### Scientific Symposium: Methodology and regulatory aspects of biotherapeutics and chemotherapeutics

Chair: C. Twelves (United Kingdom)

Chair: J.-P. Bizzari (France)

#### Introduction

Speaker: C. Twelves (United Kingdom)

#### RECIST 1.1

Speaker: E.A. Eisenhauer (Canada)

#### New imaging in cancer clinical trials

Speaker: B. Morgan (United Kingdom)

#### A new paradigm for immunotherapy: novel endpoints

Speaker: A. Hoos (USA)

#### "Clinical benefit": myth or reality?

Speaker: C. Twelves (United Kingdom)

#### Concluding remarks

Speaker: J.-P. Bizzari (France)

### TUESDAY 22 SEPTEMBER 2009

■ 13:30-14:30

#### Special Session: Individualisation of treatment based on pharmacokinetics and pharmacogenomics

Chair: P. Hartuig (Denmark)

#### Population-based PK/PD modelling

Speaker: S. Kästner (Sweden)

#### Genotyping and phenotyping

Speaker: H.J. Guchelaar (The Netherlands)

#### Discussion and roundup

### WEDNESDAY 23 SEPTEMBER 2009

■ 13:30-14:30

#### Special Session: Special session on regulatory issues

Chair: D. Lacombe (Belgium)

#### Harmonisation of regulatory requirements between the regions

Speaker: F. Pignatti (United Kingdom)

Academic clinical trials: can they serve regulatory purposes?

Speaker: To be announced

Discussion and roundup

#### ■ 17:00-18:00

**Debate: This house believes that genomic signatures will be useful for personalised medicine**

Moderator: J. Soria (France)

Speaker in favour: R. Bernards

(The Netherlands)

Seconder: F. Cardoso (Belgium)

Speaker against: K.K. Jain (Switzerland)

Seconder: E. Domany (Israel)

### THURSDAY 24 SEPTEMBER 2009

#### ■ 09:00-11:00

**Scientific Symposium: Monitoring and management of adverse drug events**

Chair: A. Astier (France)

Chair: K. Meier (Germany)

Introduction

Speaker: A. Astier (France)

Management of adverse drug events

Speaker: U. Jaehde (Germany)

Identification and prevention of drug-drug interactions

Speaker: A. Liekweg (Germany)

Adverse drug events of targeted therapies

Speaker: To be announced

Prevention therapy of fatigue

Speaker: P. Hartvig (Denmark)

Concluding remarks

Speaker: K. Meier (Germany)

#### ■ 11:15-12:15

**Special Session: Trial methodology**

Chair: P. Paoletti (USA)

The role of randomised trials and surrogate biomarkers in early clinical development

Speaker: M. Buyse (Belgium)

Integration of diagnostic markers into the development process of targeted agents

Speaker: R. Simon (USA)

Discussion and roundup

## RADIOTHERAPY / RADIOBIOLOGY

### MONDAY 21 SEPTEMBER 2009

#### ■ 08:00-08:45

**Teaching Lecture: Hadron therapy**

Speaker: J. Debus (Germany)

#### ■ 13:30-14:30

**Special Session: DNA repair of radiation damage**

Chair: D. Zips (Germany)

What is new in DNA repair of radiation damage?

Speaker: G. Iliakis (Germany)

How can we utilise DNA repair assays in prediction of radiation response?

Speaker: A. Kiltie (United Kingdom)

Discussion and roundup

#### ■ 15:30-17:30

**Scientific Symposium: GENEPI: genetic prediction of radiation damage - where do we stand?**

Chair: A.C. Begg (The Netherlands)

Chair: J. Overgaard (Denmark)

Introduction

Speaker: A.C. Begg (The Netherlands)

European tissue and database infrastructure

Speaker: K. Haustermans (Belgium)

Low dose cell responses - predictors of normal tissue damage after radiotherapy?

Speaker: P. O'Neill (United Kingdom)

Genetic markers of normal tissue effects after radiotherapy

Speaker: E. Dikomey (Germany)

Gene level and epigenetic predictors

Speaker: J. Alsner (Denmark)

Concluding remarks

Speaker: J. Overgaard (Denmark)

### TUESDAY 22 SEPTEMBER 2009

#### ■ 08:00-08:45

**Teaching Lecture: The value of new imaging technology for target volume delineation**

Speaker: V. Khoo (United Kingdom)

#### ■ 13:30-14:30

**Special Session: Very late normal tissue damage after radiotherapy**

Chair: S.M. Bentzen (USA)

Dose distribution and risk

Speaker: K.R. Trott (United Kingdom)

Long term risks after radiotherapy of testicular cancer

Speaker: S.D. Fossa (Norway)

Discussion and roundup

#### ■ 14:45-16:45

**Scientific Symposium: Biological imaging for adaptive radiotherapy**

Chair: V. Gregoire (Belgium)

Chair: V. Khoo (United Kingdom)

Introduction

Speaker: V. Gregoire (Belgium)

Biological imaging in treatment planning

Speaker: M. Alber (Germany)

Clinical status of bio-imaging for radiotherapy

Speaker: V. Valentini (Italy)

Functional imaging methods for oncology

Speaker: N. Sibson (United Kingdom)

Validation of bio-imaging methods for radiotherapy

Speaker: D. Zips (Germany)

Concluding remarks

Speaker: V. Khoo (United Kingdom)

### WEDNESDAY 23 SEPTEMBER 2009

#### ■ 08:00-08:45

**Teaching Lecture: IMRT and biological approaches in radiotherapy for prostate cancer**

Speaker: R. Bristow (Canada)

#### ■ 13:30-14:30

**Special Session: Cancer stem cells and radiation resistance**

Chair: R. Bristow (Canada)

Radioresistance of cancer stem cells

Speaker: F. Pajonk (USA)

Cancer stem cells as determinant of tumour radioresistance

Speaker: M. Baumann (Germany)

Discussion and roundup

#### ■ 14:45-16:45

**Scientific Symposium: Targeting in radiotherapy**

Chair: To be announced

Chair: J. Bourhis (France)

Introduction

Speaker: To be announced

Targeting the tumour stroma

Speaker: N. Cordes (Germany)

How to address interlinkage of pathways

Speaker: H.P. Rodemann (Germany)

Improving radiotherapy by targeting the bone marrow derived stroma

*Speaker: M. Brown (USA)*

The experience from EPO

*Speaker: J. Overgaard (Denmark)*

Concluding remarks

*Chair: J. Bourhis (France)*

■ 17:00-18:00

**Debate: This house believes that hypofractionation should be standard of care in breast cancer**

*Moderator: H. Bartelink (The Netherlands)*

*Speaker in favour: J. Yarnold (United Kingdom)*

*Second: W. Budach (Germany)*

*Speaker against: J. Overgaard (Denmark)*

*Second: J. Jassem (Poland)*

#### THURSDAY 24 SEPTEMBER 2009

■ 08:00-08:45

**Teaching Lecture: Personalised radiotherapy - what is evidence-based?**

*Speaker: C. Belka (Germany)*

■ 11:15-12:15

**Special Session: New approaches for evidence generation of novel radiation technologies**

*Chair: D.R. Olsen (Norway)*

Assessing clinical benefit from new radiation oncology technologies

*Speaker: S.M. Bentzen (USA)*

Development and assessment of novel radiation technique - a medical physics perspective

*Speaker: D. Jaffray (Canada)*

Discussion and roundup

#### SARCOMA: SOFT TISSUE AND BONE

#### WEDNESDAY 23 SEPTEMBER 2009

■ 13:30-14:30

**Special Session: Sarcoma orientated networks of excellence in Europe II**

*Chair: J.-Y. Blay (France)*

EuroBoNet

*Speaker: P.C.W. Hogendoorn (The Netherlands)*

ConticaBase, the virtual bank of Conticanet

*Speaker: J.-M. Coindre (France)*

Discussion and roundup

■ 14:45-16:45

**Scientific Symposium: Special therapies for special sarcoma subtypes**

*Chair: P. Schöffski (Belgium)*

Introduction

*Speaker: P. Schöffski (Belgium)*

Taxanes in angiosarcomas

*Speaker: M. Schlemmer (Germany)*

Aromatase-inhibitors in gynaecological sarcomas

*Speaker: A. Poveda Velasco (Spain)*

Gemcitabine-based therapy for leiomyosarcomas? For All?

*Speaker: I. Ray-Coquard (France)*

Tyrosine-kinase inhibitors in very rare sarcoma subtypes

*Speaker: J.-Y. Blay (France)*

Concluding remarks

*Speaker: P. Schöffski (Belgium)*

#### THURSDAY 24 SEPTEMBER 2009

■ 08:00-08:45

**Teaching Lecture: How to choose your treatment options for desmoids**

*Speaker: A. Gronchi (Italy)*

■ 11:15-12:15

**Special Session: Sarcomas in adolescents**

*Chair: To be announced*

Managing sarcomas in teenagers and young adults

*Speaker: J. Whelan (United Kingdom)*

Biological mechanisms underlying differences in outcomes between children and adolescents

*Speaker: To be announced*

Discussion and roundup

#### SURGICAL ONCOLOGY

#### MONDAY 21 SEPTEMBER 2009

■ 08:00-08:45

**Teaching Lecture: Image-guided surgery**

*Speaker: C.W.G.M. Lowik (The Netherlands)*

■ 13:30-14:30

**Special Session: Management of peritoneal disease**

*Chair: I. Taylor (United Kingdom)*

Present and future of HIPEC in colorectal carcinomatosis

*Speaker: D. Elias (France)*

Comprehensive management of gastrointestinal cancer: focus on appendiceal mucinous neoplasms and gastric cancer

*Speaker: P.H. Sugarbaker (USA)*

Discussion and roundup

■ 15:30-17:30

**Scientific Symposium: Quality assurance and audit in colorectal cancer in Europe**

*Chair: C.J.H. van de Velde (The Netherlands)*

*Chair: L. Pahlman (Sweden)*

Introduction

*Speaker: C.J.H. van de Velde (The Netherlands)*

The Norwegian programme

*Speaker: A. Wibe (Norway)*

The Swedish programme

*Speaker: L. Pahlman (Sweden)*

The UK programme

*Speaker: J. Smith (United Kingdom)*

An ECCO initiative for Europe

*Speaker: C.J.H. van de Velde (The Netherlands)*

Concluding remarks

*Speaker: L. Pahlman (Sweden)*

#### TUESDAY 22 SEPTEMBER 2009

■ 08:00-08:45

**Teaching Lecture: Mission accomplished or work in progress - laparoscopic vs open colorectal surgery**

*Speaker: W. Schwenk (Germany)*

■ 13:30-14:30

**Special Session: The management of GIST tumours**

*Chair: P. Naredi (Sweden)*

Surgery perspective

*Speaker: P. Hohenberger (Germany)*

Medical oncology perspective

*Speaker: S. Sleijfer (The Netherlands)*

Discussion and roundup

#### WEDNESDAY 23 SEPTEMBER 2009

■ 08:00-08:45

**Teaching Lecture: An update of sentinel node biopsy on breast cancer**

*Speaker: R.E. Mansel (United Kingdom)*

■ 13:30-14:30

**Special Session: Sentinel node staging and clinical implications in GI tract**

*Chair: T. Lehnert (Germany)*

**Any value in colorectal cancer?**

Speaker: R.A.E.M. Tollenaar  
(The Netherlands)

**Oesophagus/stomach cancer**

Speaker: P.M. Schlag (Germany)

**Discussion and roundup****THURSDAY 24 SEPTEMBER 2009****08:00-08:45****Teaching Lecture: T1/T2 rectal cancer treatment**

Speaker: N.J. Mortensen (United Kingdom)

**11:15-12:15****Special Session: Lymphadenectomy for GI cancer - does it make a difference?**

Chair: C.J.H. van de Velde (The Netherlands)

**Oesophagus cancer**

Speaker: T. Lerut (Belgium)

**Gastric cancer**

Speaker: S.A. Hundahl (USA)

**Colorectal cancer**

Speaker: P.M. Schlag (Germany)

**Discussion and roundup****SYMPTOM SCIENCE****WEDNESDAY 23 SEPTEMBER 2009****08:00-08:45****Teaching Lecture: Antiemetics: state-of-the-art**

Speaker: J. Herrstedt (Denmark)

**14:45-16:45****Scientific Symposium: Symptom management: from molecular biology to bedside including pain and cachexia**

Chair: S. Kaasa (Norway)

Chair: M. Fallon (United Kingdom)

**Introduction**

Speaker: M. Fallon (United Kingdom)

**Genotyping - does it matter in clinical practice for pain and cachexia**

Speaker: K.C. Fearon (United Kingdom)

**Assessment and classification of pain and cachexia**

Speaker: S. Kaasa (Norway)

**Cancer pain treatment. New approaches based upon the WHO pain ladder**

Speaker: M. Fallon (United Kingdom)

**Treatment of cachexia-a preventive or symptomatic approach?**

Speaker: F. Strasser (Switzerland)

**Concluding remarks**

Speaker: S. Kaasa (Norway)

**THURSDAY 24 SEPTEMBER 2009****09:00-11:00****Scientific Symposium: Communication crisis in oncology**

Chair: M. Aapro (Switzerland)

Chair: N.I. Cherny (Israel)

**Introduction**

Speaker: M. Aapro (Switzerland)

**Managing the family which demands that the patient not to be told**

Speaker: N.I. Cherny (Israel)

**Discussing a treatment error with the patient and his/her family**

Speaker: A. Surbone (Italy)

**When the patient doesn't want the treatment that you think they need**

Speaker: To be announced

**Raising end of life issues when the patient is still focused on treatment**

Speaker: L. Deliens (Belgium)

**Concluding remarks**

Speaker: N.I. Cherny (Israel)

**TRANSLATIONAL RESEARCH****MONDAY 21 SEPTEMBER 2009****15:30-17:30****Scientific Symposium: Resistance mechanisms to EGFR and HER2 inhibitors and strategies to overcome them**

Chair: F. Cappuzzo (Italy)

Chair: Y. Yarden (Israel)

**Introduction**

Speaker: F. Cappuzzo (Italy)

**An overview of resistance to anti-EGFR/HER2 agents**

Speaker: J. Baselga (Spain)

**PI3 kinase**

Speaker: K. Berns (The Netherlands)

**IGF-I receptor**

Speaker: F.J. Esteva (USA)

**RAS**

Speaker: A. Bardelli (Italy)

**Concluding remarks**

Speaker: Y. Yarden (Israel)

**TUESDAY 22 SEPTEMBER 2009****08:00-08:45****Teaching Lecture: DNA replication proteins as biomarkers in cancer****DNA replication proteins as biomarkers in cancer**

Speaker: R. Laskey (United Kingdom)

**Minichromosome maintenance proteins as markers for cancer screening**

Speaker: N. Coleman (United Kingdom)

**17:00-18:00****Educational Symposium: All you wanted to know about cancer stem cells but were afraid to ask**

Chair: M. Alison (United Kingdom)

**Stem cells and digestive organ cancer**

Speaker: M. Alison (United Kingdom)

**Breast cancer stem cells**

Speaker: B. Groner (Germany)

**Cancer stem cells in haematological malignancies - implications for understanding pathogenesis and targeted therapy**

Speaker: H.E. Johnsen (Denmark)

**WEDNESDAY 23 SEPTEMBER 2009****13:30-14:30****Special Session: Imaging in drug development**

Chair: E. Aboagye (United Kingdom)

**Imaging in early drug development - the pharmacology audit trail**

Speaker: S. Galbraith (USA)

**Imaging in Phase I-III trials**

Speaker: To be announced

**Discussion and roundup****14:45-16:45****Scientific Symposium: Targeting tumour cell signalling**

Chair: To be announced

Chair: R. Marais (United Kingdom)

**Introduction**

Speaker: To be announced

**The RAF-kinase family and cancer**

Speaker: R. Marais (United Kingdom)

**Therapeutic strategies for targeting BRAF in human cancer**

Speaker: D. Solit (USA)

**The MET oncogene: physiology and pathology of invasive growth**

Speaker: P.M. Comoglio (Italy)

**MET inhibitors in cancer therapy**

Speaker: To be announced

**Concluding remarks**

Speaker: R. Marais (United Kingdom)

**17:00-18:00****Special Session: Circulating tumour cells**

Chair: J. de Bono (United Kingdom)

Methods for detection of circulating tumour cells: potential & limitations  
*Speaker: C. Panabieres (France)*

Characterisation and monitoring of circulating tumour cells  
*Speaker: K. Pantel (Germany)*

The prognostic and therapeutic implications of circulating tumour cells in breast cancer  
*Speaker: O. Fodstad (Norway)*

Discussion and roundup

## YOUNG ONCOLOGISTS

### WEDNESDAY 23 SEPTEMBER 2009

#### ■ 08:00-08:45

Teaching Lecture: The challenge of interacting with patients  
*Speaker: L. Fallowfield (United Kingdom)*

#### ■ 09:00-11:00

Scientific Symposium: FLIMS Symposium and ECCO/EJC Award

*Chair: To be announced*  
*Chair: O. Belvedere (United Kingdom)*

The Flims Workshop  
*Speaker: To be announced*

Flims Alumni Club (FAC)  
*Speaker: M. Erman (Turkey)*

Presentation of a Flims study  
*Speaker: O. Belvedere (United Kingdom)*

Presentation of a Flims study  
*Speaker: To be announced*

Q & A / discussion

Introduction of the ECCO/EJC Young Investigator Award winner  
*Speaker: To be announced*

ECCO/EJC Young Investigators Award  
*Award Lecturer: To be announced*

#### ■ 13:30-14:30

Special Session: Oncology societies: why?

*Chair: M. Ballieu (Belgium)*

Introduction  
*Speaker: M. Ballieu (Belgium)*

ESSO  
*Speaker: To be announced*

ESTRO  
*Speaker: L.P. Muren (Denmark)*

ESMO  
*Speaker: E. Martinelli (Italy)*

EACR  
*Speaker: R.J. White (United Kingdom)*

Discussion and roundup

#### ■ 14:45-16:45

Scientific Symposium: Innovations in early clinical trials

*Chair: S. Di Cosimo (Spain)*  
*Chair: C. Twelves (United Kingdom)*

Introduction  
*Speaker: S. Di Cosimo (Spain)*

Phase 0 clinical trials: facts and promise  
*Speaker: To be announced*

Use of biologics in drug development  
*Speaker: T. Morgillo (Italy)*

Phase I setting up and running: the fellow point of view  
*Speaker: To be announced*

Novel tool for drug efficacy testing  
*Speaker: M. Ignatidis (Belgium)*

Concluding remarks  
*Speaker: C. Twelves (United Kingdom)*

### THURSDAY 24 SEPTEMBER 2009

#### ■ 08:00-08:45

Teaching Lecture: Evidence-based medicine: development and implementation of guidelines in oncology  
*Speaker: N. Paulidis (Greece)*

#### ■ 09:00-11:00

Scientific Symposium: Multidisciplinary teams in cancer care

*Chair: To be announced*  
*Chair: E. De Azambuja (Belgium)*

Multidisciplinary teams: what are they, how do they work?  
*Speaker: H.J. Schmoll (Germany)*

The impact of MDT meetings on cancer patient management  
*Speaker: A.-J. Ramirez (United Kingdom)*

Moderator  
*Speaker: To be announced*

Case presentation 1: Lung - Radiotherapist  
*Speaker: To be announced*

Case presentation 2: Breast - Medical Oncologist  
*Speaker: C. Palmieri (United Kingdom)*

Case presentation 3: Rectal - Surgeon  
*Speaker: To be announced*

Discussion and roundup

#### ■ 11:15-12:15

Special Session: Career development opportunities after your degree

*Chair: F. Ciardiello (Italy)*

Clinical fellowship opportunities in Europe  
*Speaker: M. Piccart (Belgium)*

Clinical fellowship opportunities in the U.S.  
*Speaker: J. King (USA)*

Discussion and roundup

